ACE2 (19-45)[T2A,I3L,A7hY,N15M,A18L,F22L,S25L,S26A]

General Information


DRACP ID  DRACP04380

Peptide Name   ACE2 (19-45)[T2A,I3L,A7hY,N15M,A18L,F22L,S25L,S26A]

Sequence  SALEEQXKTFLDKFMHELEDLLYQLAL

Sequence Length  27

UniProt ID  Q9BYF1 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antiviral



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C143H220N32O43S

Absent amino acids  CGINPRVW

Common amino acids  L

Mass  368153

Pl  4.1

Basic residues  3

Acidic residues  6

Hydrophobic residues  11

Net charge  -3

Boman Index  -3126

Hydrophobicity  -15.19

Aliphatic Index  108.52

Half Life 
  /

Extinction Coefficient cystines  1490

Absorbance 280nm  57.31

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 33580154

Title  Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection

Doi Not available

Year  2021

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  19260

DRACP is developed by Dr.Zheng's team.